Vontobel Financial Products GmbH Share Price

Certificat

DE000VU9ZFW9

Delayed Deutsche Boerse AG 09:33:20 03/06/2024 BST
43.13 EUR +1.36% Intraday chart for Vontobel Financial Products GmbH
1 month-12.61%
3 months-37.61%
Date Price Change
03/06/24 43.13 +1.36%
31/05/24 42.55 +2.21%
30/05/24 41.63 -1.58%
29/05/24 42.3 -4.73%
28/05/24 44.4 -2.20%

Delayed Quote Deutsche Boerse AG

Last update June 03, 2024 at 09:33 am

More quotes

Static data

Product typeReverse Convertibles
Buy / SellCALL
Underlying EVOTEC SE
IssuerLogo Issuer Vontobel Vontobel
WKN VU9ZFW
ISINDE000VU9ZFW9
Date issued 18/07/2023
Strike 23
Maturity 20/09/2024 (110 Days)
Parity 0.02 : 1
Emission price 100
Emission volume N/A
Settlement both
Currency EUR

Technical Indicators

Highest since issue 105.1
Lowest since issue 41.55
Spread 1
Spread %0.23%

Company Profile

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Sector
-
More about the company

Ratings for Evotec SE

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Evotec SE

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
8.655 EUR
Average target price
20.79 EUR
Spread / Average Target
+140.21%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW